Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.

BMC Pharmacology & Toxicology
R DobbinsBarkate Hanmant

Abstract

Patients with type 2 diabetes mellitus (T2DM) are characterized by an elevated glycemic index and are at a higher risk for complications such as cardiovascular disease, nephropathy, retinopathy and peripheral neuropathy. Normalization of glycemic index can be achieved by dosing combinations of metformin with other anti-diabetic drugs. The present study (Clintrials number NCT00519480) was conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of remogliflozinetabonate, an SGLT2 inhibitor, withdoses (500 mg and 750 mg BID) greater than the commercial dose (100 mg BID)in combination with metformin with minimum daily dose of 2000 mg given in two divided doses. This was a randomized, double-blinded, repeat dose study in 50 subjects with T2DM. The study was conducted in three phases; run-in, randomization, and treatment. All subjects were on a stable metformin dosing regimen. Cohort 1 subjects were randomly allocated to receive either remogliflozin etabonate 500 mg BID or placebo BID (2:1) in addition to metformin. Cohort 2 subjects were administered with either remogliflozin etabonate 750 mg BID or placebo BID (2:1) in addition to metformin for 13 days. All the subjects were assessed for safety (advers...Continue Reading

References

Jul 10, 2010·Journal of the American Society of Nephrology : JASN·Volker VallonTimo Rieg
Jun 20, 2013·Blood Pressure·UNKNOWN Task Force for the management of arterial hypertension of the European Society of Hypertension, UNKNOWN Task Force for the management of arterial hypertension of the European Society of Cardiology
Oct 2, 2014·Diabetes Care·Ilkka TikkanenUNKNOWN EMPA-REG BP Investigators
Nov 27, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sanjay Kalra
May 3, 2015·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Robin O'Connor-SemmesWilliam O Wilkison
Aug 20, 2015·Expert Opinion on Investigational Drugs·Nasser Mikhail
Dec 17, 2016·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·E L AndradeJ B Calixto
Aug 5, 2017·Diabetologia·Graham RenaEwan R Pearson
Mar 16, 2018·Molecular Therapy. Methods & Clinical Development·Beatriz Silva Lima, Mafalda Ascensão Videira

❮ Previous
Next ❯

Software Mentioned

WinNonlin

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.